Phase II randomized controlled trial of epirubicin hydrochloride and miriplatin hydrate as anticancer agents for transcatheter arterial chemoembolization of hepatocellular carcinoma
Not Applicable
Recruiting
- Conditions
- hepatocellular carcinoma
- Registration Number
- JPRN-UMIN000011785
- Lead Sponsor
- Takasaki General Medical Center, National Hospital Organization
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
1) Drug allergy by miriplatin or epirubicin. 2) Extrahepatic metastasis. 3) Portal venous invasion in the major trunk or first order branch. 4) Remarkable arterio-portal or arterio-venous shunting. 5) Hepatic artery occlusion. 6) Biliary reconstruction. 7) Comorbid diseases *Cardiac failure *Renal failure *Active infection *Active gastrointestinal bleeding *Active associated cancers *Hepatic encephalopathy *Refractory ascites or pleural effusion 8) Fever (more than 38 degrees Celsius) 9) Allergy to contrast media 10) Pregnant or lactating 11) Other reasons not indicated to this study judged by doctors.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method